Neurocrine Biosciences, a California-based pharmaceutical firm, has announced an intention to press their tardive dyskinesia treatment into US trials under the federal Food & Drug Administration’s Investigational New Drug program.

A previous trial taken up in Canada among healthy male volunteer candidates offered positive feedback, showing no major negative reactions to the drug treatment, including no substantially abnormal ECG findings. The company characterized the drug’s performance in these first phase tests as well-tolerated and working toward its primary function.

The treatment process inhibits brain chemicals that off-set the levels of dopamine that the brain receives in communications between nerves. Neurocrine notes that this drug also marginalizes any change to other monoamines in the brain, which otherwise could have increased side-effects.

This drug has been offered to the public as a possible treatment for not only tardive dyskinesia, but similar disorders like Tourette’s syndrome and even some forms of schizophrenia.

If you have developed tardive dyskinesia after using the drug Reglan, you may be eligible for compensation from pharmaceutical companies. Contact the Reglan lawsuit attorneys of Williams Kherkher at 800-761-3187 today to discuss your rights and options.